• Mechanism of Action
• Directly inhibits the binding of androgens to androgen receptors.
• • Pharmacology
  •  Interacts only with androgen receptors, producing no progestin or glucocorticoid effects.

Clinical Use

• • Indication
  • Androgen deprivation therapy for metastatic castrate-resistant prostate cancer.
• • Contraindications
  • Seizure disorders.
• • Adverse Effects